These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17969785)

  • 1. [Recent progress in the medical treatment of benign prostatic hyperplasia].
    Cornu JN; Rouprêt M
    Prog Urol; 2007 Sep; 17(5 Suppl 1):1029-32. PubMed ID: 17969785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug therapy for benign prostatic syndrome (BPS)].
    Berges R
    Aktuelle Urol; 2006 Sep; 37(5):351-62. PubMed ID: 17004180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benign prostatic hyperplasia: medical therapy].
    Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
    MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term outcome of medical therapy for BPH.
    Madersbacher S; Marszalek M; Lackner J; Berger P; Schatzl G
    Eur Urol; 2007 Jun; 51(6):1522-33. PubMed ID: 17416456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA].
    Spivak LG; Lokshin KL; Vinarov AZ
    Urologiia; 2015; (4):125-33. PubMed ID: 26665780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
    Naruoka T; Suzuki Y; Furuta A; Endo K; Sugaya S; Egawa S
    Hinyokika Kiyo; 2008 May; 54(5):341-4. PubMed ID: 18546857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility.
    Tiwari A
    IDrugs; 2009 Jun; 12(6):381-93. PubMed ID: 19517319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent progress in basic research concerning the management of benign prostatic hyperplasia].
    Cornu JN; Rouprêt M
    Prog Urol; 2007 Sep; 17(5 Suppl 1):1020-2. PubMed ID: 17969782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pikamilone treatment of benign prostatic hyperplasia].
    Tolstova SS
    Urologiia; 1999; (5):6-7. PubMed ID: 11150159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of alpha1-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench].
    Kojima Y; Hayase M; Imura M; Okada S; Kubota Y; Sasaki S; Hayashi Y; Kohri K
    Hinyokika Kiyo; 2008 Jun; 54(6):457-62. PubMed ID: 18634446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fushile: a safe and effective therapeutic for benign prostatic hyperplasia].
    Shang XJ; Liu ZY; Liu ZF; Sun YH; Huang YF
    Zhonghua Nan Ke Xue; 2008 Mar; 14(3):227-30. PubMed ID: 18488335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.
    Speakman M; Batista J; Berges R; Chartier-Kastler E; Conti G; Desgrandchamps F; Dreikorn K; Lowe F; O'Leary M; Perez M; Trachtenberg J; Tubaro A; Meesen B; Smets L; Stoevelaar H
    Prostate Cancer Prostatic Dis; 2005; 8(4):369-74. PubMed ID: 16130013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia.
    Desgrandchamps F
    Eur Urol; 1997; 32 Suppl 1():28-31. PubMed ID: 9218940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an alpha1-adrenoceptor blocker].
    Kato S; Kusaka M; Shiroki R; Izumitani M; Asano H; Ooki T; Yanaoka M; Hoshinaga K
    Hinyokika Kiyo; 2008 Mar; 54(3):173-7. PubMed ID: 18411771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.